Research Paper Volume 13, Issue 16 pp 20661—20683
METTL21B is a prognostic biomarker and potential therapeutic target in low-grade gliomas
Figure 1. Expression of METTL21B in LGG. The expression differences of METTL21B between LGG tissues and normal samples in TCGA+GTEx (A), Rembrandt (B) and GSE16011 (C) dataset; (D) The correlation between expression and methylation of METTL21B. (E) Copy number gain/amplification of METTL21B markedly increased the mRNA expression. *P<0.05; **P<0.01; ***P<0.001; ****P<0.0001.